AB Science S.A. (ENXTPA: AB)
Health Care · Pharmaceuticals · FR
€0.72
+3.90% today · -45.0% 1Y
AB Science S.A. (ENXTPA: AB) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $64.73M and employs 31 people.
Over the last twelve months the share price has lost 45.0%, trading between 0.50 and 1.68.
Tweenvest scores AB Science S.A. across four factors: quality 13/100, value 41/100, growth 50/100. Its strongest factor is growth.
AB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $64.73M
- Revenue (TTM)
- $1.38M
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- 1.17
- 52-week high
- €1.68
- 52-week low
- €0.50
- Avg volume (3M)
- —
- Shares outstanding
- 80.01M
- Employees
- 31
- Next earnings
- —
About AB Science S.A.
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.
- ISIN
- FR0010557264
- Founded
- 2001
- Listed since
- Apr 26, 2010
- Exchange
- Euronext Paris
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,232.45 | -0.10% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $272.93 | -0.08% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF371.90 | -0.51% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.29 | -1.18% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.